Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - A Safety Study (S30.005)

Voldsgaard, Ana; Bager, Peter; Kapel, Christian M. O.; Roepstorff, Allan; Thamsborg, Stig Milan; Soendergaard, Helle; Melbye, Mads; Aakeson, Per; Leffers, Anne-Mette; Garde, Ellen; Siebner, Hartwig R.; Sellebjerg, Finn; Soerensen, Per Soelberg

doi:10.1212/wnl.78.1_meetingabstracts.s30.005

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these hygiene scores were associated with MS risk, neither the presence of antibody titers against Ascaris or Stronglyodies nor self-report of past parasitic infection or treatment had significant links to risk of MS. Some prior data suggests a favorable impact of parasitic infection on disease course among MS patients [11][12][13], and helminth infection has been shown to bias the immune system towards Th2 and regulatory T-cell responses [14]. However, due to our small sample size and the potential misclassification of exposure for both the self-reported and serological measures, it is difficult to draw conclusions regarding parasitic infection.…”

Section: Discussionmentioning

confidence: 90%

Epstein-Barr Virus, Hygiene, and Multiple Sclerosis in Mexico City

Massa¹

2013

J Neurol Disord

View full text Add to dashboard Cite

Background/Aims: We studied whether serological antibody titers against Epstein-Barr virus (EBV) were related to multiple sclerosis (MS) risk in Mexico City, a population undergoing an epidemiological transition. Additionally, we explored the association between markers of hygiene and intestinal parasite infection and MS prevalence. Methods:We conducted a hospital based case-control study in Mexico City; 52 incident MS cases. Childhood and adult hygiene scores were created using information from questionnaires. 51 cases and 51 controls provided blood samples for biomarker analyses.Results: There was a 3-fold increase in risk of MS with each 1 unit increase in anti-EBNA1 titer (OR 3.02, 95% CI: 1.01-9.02). Increasing childhood and adult hygiene scores were associated with a modestly increased risk of MS (OR childhood 1.20, 95% CI: 1.04-1.38; OR adult 1.28, 95% CI: 1.04-1.58). We found no association between antibody titer to neither Stronglyloides nor Ascaris and MS risk. Conclusion:High anti-EBNA1 antibody titers appears to be associated with increased MS risk even in a region where MS had historically low incidence and infectious mononucleosis is rare, providing further support for the postulated role of EBV in MS etiology. We also found moderate support for a role of higher 'hygiene' being associated with susceptibility to MS.

show abstract

Section: Discussionmentioning

confidence: 90%

Epstein-Barr Virus, Hygiene, and Multiple Sclerosis in Mexico City

Massa¹

2013

J Neurol Disord

View full text Add to dashboard Cite

show abstract

“…An open-label, MRI assessor-blinded safety study of 10 RRMS patients treated with 2,500 TSO orally for 3 months (TRIMS A) was conducted by Voldsgaard et al at the Danish Multiple Sclerosis Centre at Copenhagen University Hospital, Denmark (Voldsgaard et al 2012). Six from ten patients were concomitantly treated with β-interferon.…”

Section: Clinical Trials With Helminths In Msmentioning

confidence: 99%

“…MRI was performed every 3 weeks. The investigators concluded that TSO was safe and well-tolerated but that no clinical, MRI or immunological signals suggestive of a benefit were observed (Voldsgaard et al 2012). The trial design was not adapted to test drug effectiveness, but safety.…”

Section: Clinical Trials With Helminths In Msmentioning

confidence: 99%

Emerging and Evolving Topics in Multiple Sclerosis Pathogenesis and Treatments

Flamme¹,

Orian²

2015

Current Topics in Behavioral Neurosciences

View full text Add to dashboard Cite

Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats.With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on ''translational medicine'' and cutting-edge technologies. Preclinical and clinical trials for the development of new diagnostics and therapeutics as well as prevention efforts are covered whenever possible.

show abstract

“…Therefore no evidence of efficacy was observed in this population. 32 The evidence of safety provided by the study in patients with newly diagnosed RRMS described above was considered sufficient by the US Food and Drug Administration to allow the same team to conduct an efficacy study in the same population (Helminth-induced Immunomodulation Therapy study phase 2; ClinicalTrials.gov identifier NCT00645749). Another trial is underway in patients with RRMS.…”

Section: Evidence Of the Efficacy Of Tsomentioning

confidence: 99%